


Pharmacokinetics of Ruxolitinib in Patients With Atopic Dermatitis Treated With Ruxolitinib Cream

Xiaohua Gong, Xuejun Chen, Michael E. Kuligowski, Xing Liu, Xiang Liu, Evan Cimino, Ryan McGee, Swamy Yeleswaram*


Incyte Corporation, Wilmington, DE, USA

*Corresponding author: Swamy Yeleswaram; email: yeleswaram@incyte.com

Online Resource 1. Mean (95% CI) absolute neutrophil count over time after application of ruxolitinib cream in the phase 3 studies combined. *BQL* ruxolitinib cream treated but PK samples below the quantification limit, C_{ss} steady state concentration, *Q1 to Q4* 1st to 4th quartiles of ruxolitinib C_{ss} during VC period, *PK* pharmacokinetic, *VC* vehicle-controlled.



Online Resource 2. Mean (95% CI) hemoglobin levels over time after application of ruxolitinib cream in the phase 3 studies combined. *BQL* ruxolitinib cream treated but PK samples below the quantification limit, C_{ss} steady state concentration, *Q1* to *Q4* 1st to 4th quartiles of ruxolitinib C_{ss} during VC period, *PK* pharmacokinetic, *VC* vehicle-controlled.



Online Resource 3. Mean (95% CI) of MPV over time after application of the ruxolitinib cream in the phase 3 studies combined. *BQL* ruxolitinib cream treated but PK samples below the quantification limit, *C_{ss}* steady state concentration, *Q1* to *Q4* 1st to 4th quartiles of ruxolitinib *C_{ss}* during VC period, *MPV* mean platelet volume, *PK* pharmacokinetic, *VC* vehicle-controlled.

